Rapid Emergence of SARS-CoV-2 in the Greater New York Metropolitan Area : Geolocation, Demographics, Positivity Rates, and Hospitalization for 46 793 Persons Tested by Northwell Health
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: In March 2020, the greater New York metropolitan area became an epicenter for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The initial evolution of case incidence has not been well characterized.
METHODS: Northwell Health Laboratories tested 46 793 persons for SARS-CoV-2 from 4 March through 10 April. The primary outcome measure was a positive reverse transcription-polymerase chain reaction test for SARS-CoV-2. The secondary outcomes included patient age, sex, and race, if stated; dates the specimen was obtained and the test result; clinical practice site sources; geolocation of patient residence; and hospitalization.
RESULTS: From 8 March through 10 April, a total of 26 735 of 46 793 persons (57.1%) tested positive for SARS-CoV-2. Males of each race were disproportionally more affected than females above age 25, with a progressive male predominance as age increased. Of the positive persons, 7292 were hospitalized directly upon presentation; an additional 882 persons tested positive in an ambulatory setting before subsequent hospitalization, a median of 4.8 days later. Total hospitalization rate was thus 8174 persons (30.6% of positive persons). There was a broad range (>10-fold) in the cumulative number of positive cases across individual zip codes following documented first caseincidence. Test positivity was greater for persons living in zip codes with lower annual household income.
CONCLUSIONS: Our data reveal that SARS-CoV-2 incidence emerged rapidly and almost simultaneously across a broad demographic population in the region. These findings support the premise that SARS-CoV-2 infection was widely distributed prior to virus testing availability.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 71(2020), 12 vom: 15. Dez., Seite 3204-3213 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reichberg, Samuel B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease 2019 (COVID-19) |
|---|
| Anmerkungen: |
Date Completed 27.01.2021 Date Revised 30.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa922 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312173261 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312173261 | ||
| 003 | DE-627 | ||
| 005 | 20240330232619.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa922 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM312173261 | ||
| 035 | |a (NLM)32640030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reichberg, Samuel B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid Emergence of SARS-CoV-2 in the Greater New York Metropolitan Area |b Geolocation, Demographics, Positivity Rates, and Hospitalization for 46 793 Persons Tested by Northwell Health |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: In March 2020, the greater New York metropolitan area became an epicenter for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The initial evolution of case incidence has not been well characterized | ||
| 520 | |a METHODS: Northwell Health Laboratories tested 46 793 persons for SARS-CoV-2 from 4 March through 10 April. The primary outcome measure was a positive reverse transcription-polymerase chain reaction test for SARS-CoV-2. The secondary outcomes included patient age, sex, and race, if stated; dates the specimen was obtained and the test result; clinical practice site sources; geolocation of patient residence; and hospitalization | ||
| 520 | |a RESULTS: From 8 March through 10 April, a total of 26 735 of 46 793 persons (57.1%) tested positive for SARS-CoV-2. Males of each race were disproportionally more affected than females above age 25, with a progressive male predominance as age increased. Of the positive persons, 7292 were hospitalized directly upon presentation; an additional 882 persons tested positive in an ambulatory setting before subsequent hospitalization, a median of 4.8 days later. Total hospitalization rate was thus 8174 persons (30.6% of positive persons). There was a broad range (>10-fold) in the cumulative number of positive cases across individual zip codes following documented first caseincidence. Test positivity was greater for persons living in zip codes with lower annual household income | ||
| 520 | |a CONCLUSIONS: Our data reveal that SARS-CoV-2 incidence emerged rapidly and almost simultaneously across a broad demographic population in the region. These findings support the premise that SARS-CoV-2 infection was widely distributed prior to virus testing availability | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a race | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a socioeconomic | |
| 700 | 1 | |a Mitra, Partha P |e verfasserin |4 aut | |
| 700 | 1 | |a Haghamad, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Ramrattan, Girish |e verfasserin |4 aut | |
| 700 | 1 | |a Crawford, James M |e verfasserin |4 aut | |
| 700 | 0 | |a Northwell COVID-19 Research Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Berry, Gregory J |e verfasserin |4 aut | |
| 700 | 1 | |a Davidson, Karina W |e verfasserin |4 aut | |
| 700 | 1 | |a Drach, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Duong, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Juretschko, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Maria, Naomi I |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yihe |e verfasserin |4 aut | |
| 700 | 1 | |a Ziemba, Yonah C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 71(2020), 12 vom: 15. Dez., Seite 3204-3213 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:12 |g day:15 |g month:12 |g pages:3204-3213 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa922 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 12 |b 15 |c 12 |h 3204-3213 | ||